EN DE
STOCK COMPARISON

Alivus Life Sciences vs Jiangsu Hengrui Medicine Co: Fair Value & Quality

Both stocks run through our valuation models. Here is how Alivus Life Sciences (ALIVUS) and Jiangsu Hengrui Medicine Co (600276) compare, as of Aug 17, 2026.

As of Aug 17, 2026, Fair Value Calculator sees Jiangsu Hengrui Medicine Co as the less overvalued of the two: Alivus Life Sciences trades at ₹1,387 versus a fair value of ₹614 (-56%), while Jiangsu Hengrui Medicine Co trades at ¥52.62 versus ¥25.94 (-51%).
Alivus Life Sciences
ALIVUS.NSE · INR · Healthcare
-56%
upside to fair value
overvalued
Price₹1,387
Fair Value₹614
Quality63/100
Jiangsu Hengrui Medicine Co
600276.SHG · CNY · Health Care
-51%
upside to fair value
overvalued
Price¥52.62
Fair Value¥25.94
Quality66/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Alivus Life SciencesJiangsu Hengrui Medicine Co
Valuation
30.2×P/E (TTM)43.6×
5.58×P/S (TTM)10.84×
4.27×P/B5.76×
17.8×EV/EBITDA33.0×
PEG0.93×
0.4%Dividend yield0.4%
₹5.00Dividend per share¥0.20
Profitability
22%Net margin25%
28%Operating margin32%
18%Return on equity15%
12%Return on assets9%
Growth
6%Revenue growth (YoY)13%
7.6%Avg. growth/yr (3Y)13.9%
6.5%Avg. growth/yr (5Y)2.5%
Balance & size
$1BMarket cap$52B
mixedGrowth qualityhealthy

Alivus Life Sciences leads: 8 to 4 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Alivus Life Sciencesof which business quality 61 · market factors 86 Jiangsu Hengrui Medicine Coof which business quality 68 · market factors 42
ProfitabilityMargins and returns on capital today
66
63
Quality GrowthAre margins and returns improving?
55
41
CashflowEarnings quality: real cash, not paper profit
45
82
Fin. StrengthBalance sheet, leverage, solvency risk
80
100
InvestmentDisciplined investing over empire-building
32
27
Low VolatilityCalm price path (market factor)
84
79
MomentumPrice trend over the last 3–12 months (market factor)
84
31
52W MomentumDistance to the 52-week high (market factor)
92
20
Net IssuanceBuybacks instead of dilution
81
64

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Alivus Life Sciences

DCF Models₹647
Earnings-Based₹403
Dividend Discount₹86.29
Multiples₹846
Asset-Based₹182
Growth DCF₹487
Economic Profit₹492
Growth Earnings₹903

26 of 26 models see the stock below the current price.

Jiangsu Hengrui Medicine Co

DCF Models¥37.78
Earnings-Based¥21.29
Dividend Discount¥3.82
Multiples¥23.65
Asset-Based¥6.44
Growth DCF¥39.88
Economic Profit¥18.21
Growth Earnings¥30.99

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Alivus Life Sciences
Bear ₹356Fair Value ₹614Bull ₹1,132
₹1,387 = current price (white tick)
Jiangsu Hengrui Medicine Co
Bear ¥19.95Fair Value ¥25.94Bull ¥32.81
¥52.62 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Alivus Life Sciences · Healthcare

Quality score63 · Top 25%
Fair value upside-56% · below median

Jiangsu Hengrui Medicine Co · Health Care

Quality score66 · Top 25%
Fair value upside-51% · below median

Bottom line

As of Aug 17, 2026, Fair Value Calculator sees Jiangsu Hengrui Medicine Co as the less overvalued of the two: Alivus Life Sciences trades at ₹1,387 versus a fair value of ₹614 (-56%), while Jiangsu Hengrui Medicine Co trades at ¥52.62 versus ¥25.94 (-51%).

Jiangsu Hengrui Medicine Co has the higher quality score (66/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.